Intentional Mixture Of Two Or More Micro-organisms, Cells, Or Viruses Of Different Genera Patents (Class 424/93.3)
-
Publication number: 20150118191Abstract: The present invention provides methods of designing panels of bacteriophages as therapeutic compositions against bacterial infections. The present invention also provides panels of bacteriophages for use in the prevention or treatment of bacterial infections.Type: ApplicationFiled: May 3, 2013Publication date: April 30, 2015Inventors: David Harper, Katy Blake
-
Publication number: 20150118190Abstract: The present invention relates to a composition comprising Lactobacillus rhamnosus, preferably strain ATCC53103, and Bifidobacterium animalis subsp. lactis, preferably strain DSM 15954, for use in reducing the duration and/or severity of upper respiratory tract infection (URI) in teenagers and adults. Further aspects of the invention relate to a composition comprising Lactobacillus rhamnosus and Bifidobacterium animalis subsp. lactis for use in increasing the Health-Related Quality of Life (HRQL) in teenagers and adults having upper respiratory tract infection (URI), for reducing at least one and preferably several such as two, three, four or all of the symptoms of sore throat, scratchy throat, cough, hoarseness, chest congestion and for reducing the median severity score in teenagers and adults having upper respiratory tract infection (URI).Type: ApplicationFiled: January 14, 2013Publication date: April 30, 2015Applicant: Chr. Hansen A/SInventor: Tracey Jane Smith
-
Patent number: 9011837Abstract: Endothelial implants restore vascular homeostasis after injury without reconstituting vascular architecture. Endothelial cells line the vascular epithelium and underlying vasa vasorum precluding distinction between cellular controls. Unlike blood vessels, the airway epithelium is highly differentiated and distinct from endothelial cells that line the bronchial vasa allowing investigation of the differential control tissue engineered cells may provide in airways and blood vessels. Through airway injury and cell culture models, tissue engineered implants of the bronchial epithelium and endothelium were found to promote synergistic repair of the airway through biochemical regulation of the airway microenvironment. While epithelial cells modulate local tissue composition and reaction, endothelial cells preserve the epithelium; together their relative impact was enhanced suggesting both cell types act synergistically for airway repair.Type: GrantFiled: December 6, 2013Date of Patent: April 21, 2015Assignee: Massachusetts Institute of TechnologyInventors: Elazer R. Edelman, Brett Zani
-
Patent number: 9011835Abstract: The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided.Type: GrantFiled: January 23, 2013Date of Patent: April 21, 2015Assignee: Duke UniversityInventors: John H. Sampson, Duane A. Mitchell
-
Patent number: 9011821Abstract: In some aspects, the invention provides compositions and methods for inhibiting viral infection. In some aspects, the invention provides compositions and methods useful for identifying antiviral compounds.Type: GrantFiled: June 17, 2011Date of Patent: April 21, 2015Assignee: Whitehead Institute for Biomedical ResearchInventors: Thijn R. Brummelkamp, Jan E. Carette
-
Patent number: 9011836Abstract: Disclosed are methods of administering at least two Bacillus strains to a pig, such as female breeding stock, nursery pigs, or other pigs. The Bacillus strains inhibit Clostridium in litters borne to the pig. The Bacillus strains also are useful when administered to herds lacking symptoms of Clostridium infection. Administration of the Bacillus strains improves performance of female breeding stock and in piglets borne by the female breeding stock.Type: GrantFiled: July 9, 2013Date of Patent: April 21, 2015Assignee: DuPont Nutrition Biosciences ApSInventors: Thomas G. Rehberger, Mari Ellen Davis, Ashley Baker
-
Publication number: 20150104418Abstract: A bacterial composition that inhibits E. coli O157:H7 growth by as much as 93% and Salmonella growth by as much as 97%, together with commensurate inhibition rates against the Big-Six Escherichia coli strains referred to as the non-O157 STECs that include E. coli O121:H19; E. coli O45:H2; E. coli O103:H11; E. coli O145, E. coli O26:H11; and E. coli O111. The composition is constituted of various combinations of the following four unique pathogen-inhibiting bacteria: (1) Lactobacillus animalis strain MB101; (2) Lactobacillus animalis strain MB102; (3) Enterococcus faecium strain MB505; and (4) Pediococcus acidilactici strain MB902. Each of the discovered bacteria is deposited with the American Type Culture Collection (ATCC) and respectively has an individual ATCC Accession Number.Type: ApplicationFiled: December 18, 2014Publication date: April 16, 2015Applicant: MICROBIOS, INC.Inventors: Joseph F. Flint, Matthew Ryan Garner
-
Publication number: 20150104422Abstract: A composition including a pathogen inhibiting bacterial probiotic and a fructooligosaccharide (FOS) prebiotic particularly suited as a feed additive administered to juvenile animals such as calves that promotes animal health and growth, reduces scours and mortality, and can act as an antibiotic substitute. The additive inhibits pathogen growth resulting in lower pathogen load within the animal and pathogen sheading. The prebiotic-probiotic additive includes bacteria that inhibits E. coli O157:H7 growth by as much as 93% and Salmonella growth by as much as 97%, together with commensurate inhibition rates against the Big-Six Escherichia coli strains referred to as the non-O157 STECs that include E. coli O121:H19; E. coli O45:H2; E. coli O103:H11; E. coli O145, E. coli O26:H11; and E. coli O111.Type: ApplicationFiled: December 18, 2014Publication date: April 16, 2015Applicant: MICROBIOS, INC.Inventors: Joseph F. Flint, Matthew Ryan Garner
-
Publication number: 20150104419Abstract: A feedlot administered animal feed additive that promotes animal health and growth, reduces mortality and can act as an antibiotic substitute. The additive inhibits pathogen growth resulting in lower pathogen load within the animal and reduced pathogen sheading to the environment. The additive includes bacteria that inhibits E. coli O157:H7 growth by as much as 93% and Salmonella growth by as much as 97%, together with commensurate inhibition rates against the Big-Six Escherichia coli strains referred to as the non-O157 STECs that include E. coli O121:H19; E. coli O45:H2; E. coli O103:H11; E. coli O145, E. coli O26:H11; and E. coli O111. The additive is constituted of various combinations of the following four pathogen-inhibiting bacteria: (1) Lactobacillus animalis strain MB101; (2) Lactobacillus animalis strain MB102; (3) Enterococcus faecium strain MB505; and (4) Pediococcus acidilactici strain MB902. The bacteria are deposited with the American Type Culture Collection (ATCC).Type: ApplicationFiled: December 18, 2014Publication date: April 16, 2015Applicant: MicroBios, Inc.Inventors: Joseph F. Flint, Matthew Ryan Garner
-
Publication number: 20150104420Abstract: A dairy administered animal feed additive that promotes animal health and growth, reduces scours and mortality, and can act as an antibiotic substitute. The additive inhibits pathogen growth resulting in lower pathogen load within the animal and reduced pathogen sheading to the environment. The additive includes bacteria that inhibits E. coli O157:H7 growth by as much as 93% and Salmonella growth by as much as 97%, together with commensurate inhibition rates against the Big-Six Escherichia coli strains referred to as the non-O157 STECs that include E. coli O121:H19; E. coli O45:H2; E. coli O103:H11; E. coli O145, E. coli O26:H11; and E. coli O111. The additive is constituted of various combinations of the following four pathogen-inhibiting bacteria: (1) Lactobacillus animalis strain MB101; (2) Lactobacillus animalis strain MB102; (3) Enterococcus faecium strain MB505; and (4) Pediococcus acidilactici strain MB902. The bacteria are deposited with the American Type Culture Collection (ATCC).Type: ApplicationFiled: December 18, 2014Publication date: April 16, 2015Applicant: MicroBios, Inc.Inventors: Joseph F. Flint, Matthew Ryan Garner
-
Publication number: 20150104423Abstract: The present invention relates to a microbial composition which is tailored based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from the intestine of secretor individuals. The present invention further relates to a method of tailoring a microbial composition based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from that of secretor blood group status. The present invention relates to use of the secretor status of an individual as a criterion for microbial supplementation tailored based on the differences in the spectra of microbes found between secretor and non-secretor individuals.Type: ApplicationFiled: December 19, 2014Publication date: April 16, 2015Applicant: DUPONT NUTRITION BIOSCIENCES APSInventors: Pirjo WACKLIN, Jaana MATTO, Harri MAKIVUOKKO, Jukka PARTANEN, Janne NIKKILA
-
Publication number: 20150104421Abstract: A feed additive administered to juvenile animals such as calves that promotes animal health and growth, reduces scours and mortality, and can act as an antibiotic substitute. The additive inhibits pathogen growth resulting in lower pathogen load within the animal and pathogen sheading. The additive includes bacteria that inhibits E. coli O157:H7 growth by as much as 93% and Salmonella growth by as much as 97%, together with commensurate inhibition rates against the Big-Six Escherichia coli strains referred to as the non-O157 STECs that include E. coli O121:H19; E. coli O45:H2; E. coli O103:H11; E. coli O145, E. coli O26:H11; and E. coli O111. The additive is constituted of various combinations of the following four pathogen-inhibiting bacteria: (1) Lactobacillus animalis strain MB101; (2) Lactobacillus animalis strain MB102; (3) Enterococcus faecium strain MB505; and (4) Pediococcus acidilactici strain MB902. The bacteria are deposited with the American Type Culture Collection (ATCC).Type: ApplicationFiled: December 18, 2014Publication date: April 16, 2015Applicant: MicroBios, Inc.Inventors: Joseph F. Flint, Matthew Ryan Garner
-
Patent number: 9005602Abstract: Modified viruses and methods for preparing the modified viruses are provided. Vaccines that contain the viruses are provided. The viruses can be used in methods of treatment of diseases, such as proliferative and inflammatory disorders, including cancer, and as anti-tumor and/or antiangiogenic agents. The viruses also can be used in diagnostic methods.Type: GrantFiled: August 2, 2011Date of Patent: April 14, 2015Assignee: Genelux CorporationInventors: Aladar A. Szalay, Yong A. Yu, Nanhai Chen, Qian Zhang
-
Patent number: 9005648Abstract: In alternative embodiments, the invention provides articles of manufacture comprising biocompatible nanostructures comprising PolyEther EtherKetone (PEEK) surface-modified (surface-nanopatterned) to exhibit nanostructured surfaces that promote osseointegration and bone-bonding for, e.g., joint (e.g., knee, hip and shoulder) replacements, bone or tooth reconstruction and/or implants, including their use in making and using artificial tissues and organs, and related, diagnostic, screening, research and development and therapeutic uses, e.g., as primary or ancillary drug delivery devices. In alternative embodiments, the invention provides biocompatible nanostructures that promote osseointegration and bone-bonding for enhanced cell and bone growth and e.g., for in vitro and in vivo testing, restorative and reconstruction procedures, implants and therapeutics.Type: GrantFiled: July 6, 2011Date of Patent: April 14, 2015Assignee: The Regents of the University of CaliforniaInventors: Sungho Jin, Garrett Smith, Chulmin Choi
-
Patent number: 8999318Abstract: A composition is provided that includes Bacillus subtilis 2084 (NRRL B-50013) or a strain having all of the identifying characteristics of the Bacillus subtilis 2084 (NRRL B-50013), B. subtilis 27 (NRRL B-50105) or a strain having all of the identifying characteristics of the B. subtilis 27 (NRRL B-50105), and B. licheniformis 21 (NRRL B-50134) or a strain having all of the identifying characteristics of the B. licheniformis 21 (NRRL B-50134). Animal bedding that includes the Bacillus strains is also provided, as well as a method of making the animal bedding. Also provided are methods of controlling odors from animal waste. A method of making a composition including the Bacillus strains is also provided.Type: GrantFiled: March 1, 2013Date of Patent: April 7, 2015Assignee: Dupont Nutrition Biosciences APSInventors: Marianne Cain Bellot, Keith J. Mertz, Thomas G. Rehberger
-
Publication number: 20150093360Abstract: Disclosed herein are therapeutic compositions containing non-pathogenic, germination-competent bacterial spores, for the prevention, control, and treatment of gastrointestinal diseases, disorders and conditions and for general nutritional health.Type: ApplicationFiled: March 4, 2014Publication date: April 2, 2015Applicant: Seres Health, Inc.Inventors: Gregory McKenzie, Mary-Jane Lombardo McKenzie, David N. Cook, Marin Vulic, Geoffrey von Maltzahn, Brian Goodman, John Grant Aunins, Matthew R. Henn, David Arthur Berry, Jonathan Winkler
-
Publication number: 20150093428Abstract: A 3D in vitro bi-phasic cartilage-bone organoid includes a layer of an artificial cartilage tissue, and a layer of an artificial bone tissue comprising a structure-giving scaffold and a bone marrow structure. The layer of the artificial cartilage tissue contacts at least one surface of the layer of the artificial bone tissue.Type: ApplicationFiled: February 28, 2013Publication date: April 2, 2015Applicant: TISSUSE GMBHInventors: Mark Rosowski, Shirin Fatehi-Varkani, Roland Lauster, Uwe Marx
-
Patent number: 8986674Abstract: The present invention concerns methods and compositions for the treatment of cancer and cancer cells using altered poxviruses, including a vaccinia virus that has been altered to generate a more effective therapeutic agent. Such poxviruses are engineered to be attenuated or weakened in their ability to affect normal cells. In some embodiments, methods and compositions involve poxviruses that possess mutations that result in poxviruses with diminished or eliminated capability to implement an antiviral response in a host. Poxviruses with these mutations in combination with other mutations can be employed for more effective treatment of cancer.Type: GrantFiled: November 13, 2012Date of Patent: March 24, 2015Assignee: Sillajen Biotherapeutics, Inc.Inventors: David Kirn, Steve H. Thorne
-
Publication number: 20150079039Abstract: Provided herein are compositions for improving sinus microbiota and treating sinusits. Further provided are methods of detecting imbalance in the sinus microbiota that can be indicative of sinusitis, and methods of determining whether an individual has or is at risk of developing sinusitis, e.g., chronic sinusitis.Type: ApplicationFiled: April 12, 2013Publication date: March 19, 2015Inventors: Susan Lynch, Andrew Goldberg, Steven D. Pletcher
-
Publication number: 20150079040Abstract: The invention provides probiotic bacteria and lysates thereof for use in methods of medical and cosmetic treatment. Use in the treatment of infections, including skin infections and methods involving regeneration or repair of the skin barrier are contemplated.Type: ApplicationFiled: March 15, 2013Publication date: March 19, 2015Inventors: Catherine O'Neill, Andrew McBain
-
Publication number: 20150079041Abstract: The subject of the present invention is a bacterial composition having immunomodulation properties comprising at least one strain selected from the group consisting of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798, Bifidobacterium bifidum PTA-4801 and Bifidobacterium lactis PTA-4802. An other subject of the invention is an immunomodulation method comprising the step of using the at least one strain selected from the preceding group.Type: ApplicationFiled: September 23, 2014Publication date: March 19, 2015Inventors: VERONIQUE DENNIN, Gregory John Leyer, Annick Mercenier, Sophie Nutten, Bruno Pot
-
Patent number: 8980247Abstract: According to the invention, parvoviruses such as the adeno-associated virus Type 2 (AAV2) are found to be oncolytic, selectively mediating apoptosis in cancer cells and their precursors, while leaving healthy cells intact. The invention also includes a method of killing cancer and other neoplastic and preneoplastic cells by administrating to said cells the AAV2 proteins Rep78 or Rep 68, expression constucts encoding the same, or pharmaceutical compositions comprising the same.Type: GrantFiled: December 13, 2011Date of Patent: March 17, 2015Assignee: The Penn State Research FoundationInventors: Craig M. Meyers, Samina Alam
-
Publication number: 20150050244Abstract: The present invention provides a strain of entomopathogenic Beauveria bassiana, compositions comprising the entomopathogenic fungi strain or metabolites of the strain, and the use of the entomopathogenic fungi strain and compositions as biological control agents. Methods for the biological control of phytopathogenic insects using an entomopathogenic Beauveria bassiana fungi strain or one or more metabolites thereof, optionally together with other entomopathogenic fungi including fungi selected from strains of Lecanicillium spp., Paecilomyces fumosoroseus, and compositions comprising said fungi or metabolites thereof are also provided.Type: ApplicationFiled: May 5, 2014Publication date: February 19, 2015Applicant: Greentide Limited, a New Zealand CompanyInventor: Stephen Reynold FORD
-
Publication number: 20150050245Abstract: This invention relates to controlled release formulations of probiotic bacteria and bacteriophages, including combined formulations of probiotic bacteria and bacteriophages. The formulations contain a hydrophilic agent, an electrolytic agent and a polysaccharide and may be in tablet form for oral delivery to the intestinal system. In one preferred aspect, the formulations of the present invention effect the simultaneous introduction or addition of probiotic bacteria and bacteriophages to cause the subtraction or removal of undesirable bacteria.Type: ApplicationFiled: August 14, 2014Publication date: February 19, 2015Inventors: Richard E. Herman, Timothy Gamble
-
Patent number: 8956590Abstract: The present invention encompasses compositions and methods of reducing the incidence of equine digestive disorders. A combination of either composition A (ASSURE PLUS®) and composition B (ASSURE®) or a combination of composition A (ASSURE PLUS®) and composition C (ASSURE GUARD®) may be administered to the equine.Type: GrantFiled: July 20, 2012Date of Patent: February 17, 2015Assignee: Altera International, Ltd.Inventor: Jay A. Altman
-
Publication number: 20150044173Abstract: Microbiota restoration therapy compositions and methods for manufacturing, processing, and/or delivering microbiota restoration therapy compositions are disclosed. An example method for manufacturing a microbiota restoration therapy composition may include collecting a human fecal sample and adding a diluent to the human fecal sample to form a diluted sample. The diluent may include a cryoprotectant. The method may also include mixing the diluted sample with a mixing apparatus and filtering the diluted sample. Filtering may form a filtrate. The method may also include transferring the filtrate to a sample bag and sealing the sample bag.Type: ApplicationFiled: October 2, 2014Publication date: February 12, 2015Inventors: Lee A. Jones, Courtney R. Jones, Edwin J. Hlavka, Ryan D. Gordon
-
Publication number: 20150044172Abstract: The present invention relates to probiotic compositions and methods of using such compositions. In particular, the present invention provides method of using Faecalibacterium spp. to improve weight gain, provide prophylaxis against diarrhea and/or improve feed efficiency in an animal.Type: ApplicationFiled: February 27, 2013Publication date: February 12, 2015Inventors: Rodrigo Carvalho Bicalho, Georgios Oikonomou, Andre Gustavo Vieira Teixeira
-
Publication number: 20150037285Abstract: The present invention relates to methods for transferring gastrointestinal microbiota that preserves viability and bioactivity of the microbiota, even if fastidious, anaerobic, and non-culturable organisms are present. Also provided herein are examples of how manipulating the gastrointestinal microbiota and introducing particular taxa can be used to affect host metabolic status related to weight, fat, and obesity.Type: ApplicationFiled: July 3, 2014Publication date: February 5, 2015Applicant: NEW YORK UNIVERSITYInventors: Martin J. BLASER, Laura M. COX
-
Patent number: 8940307Abstract: The present invention also relates to a method of reducing metastases in a subject comprising administering to the subject a composition comprising a multifunctional molecule comprising a first part which is capable of binding to an antigen bearing target and a second part which is capable of binding to a cell.Type: GrantFiled: September 19, 2003Date of Patent: January 27, 2015Assignee: Opsanitx LLCInventors: Andrew H. Segal, Elihu Young
-
Publication number: 20150017128Abstract: The present disclosure refers to strains of lactic bacteria and/or bifidobacteria having activity of inhibiting/reducing the growth of different biotypes of E. coli, including E. coli 0157:7 and different biotypes of clostridia, including Clostridium difficile, Listeria monocytogenes, Enterococcus sp. and Klebsiella sp. Furthermore, the present invention refers to a pharmaceutical or dietary composition or a supplement or a medical device with at least one of the said strains of bacteria, optionally in combination with acetylcysteine and/or microencapsulated gastroprotected lysozyme and/or acetylcysteine with microencapsulated gastro-protected lysozyme.Type: ApplicationFiled: September 10, 2012Publication date: January 15, 2015Inventor: Giovanni Mogna
-
Patent number: 8921060Abstract: The invention relates to the area of health-beneficial preparations and production methods thereof, in particular to the use of thermally pre-treated Lactobacillus preparations having specific bonding capacity for Streptococcus mutans for caries prophylaxis. The invention further relates to the Lactobacillus preparations and thermal pasteurization.Type: GrantFiled: October 11, 2010Date of Patent: December 30, 2014Assignee: BASF SEInventor: Bryan Cooper
-
Publication number: 20140363397Abstract: There are provided novel synthetic stool preparations comprising bacteria isolated from a fecal sample from a healthy donor. The synthetic stool preparations are used for treating disorders of the gastrointestinal tract, including dysbiosis, Clostridium difficile infection and recurrent Clostridium difficile infection, prevention of recurrence of Clostridium difficile infection, treatment of Crohn's disease, ulcerative colitis, irritable bowel syndrome, inflammatory bowel disease, and diverticular disease, and treatment of food poisoning such as salmonella. Methods of preparation and methods of use of the synthetic stool preparations are also provided.Type: ApplicationFiled: September 14, 2012Publication date: December 11, 2014Applicants: QUEEN'S UNIVERSITY AT KINGSTON, UNIVERSITY OF GUELPH, KINGSTON GENERAL HOSPITALInventors: Emma Allen-Vercoe, Elaine Olga Petrof
-
Publication number: 20140364309Abstract: The present invention relates to active compound combinations and compostions for reducing the damage of plants and plant parts as well as losses in harvested fruits or vegetables caused by insects, nematodes or phytopathogens and which have fungicidal or nematicidal or insecticidal activity including any combination of the three activities, in particular within a composition, which comprises (A) Fluopyram, (B) a spore-forming bacterium of the genera Bacillus, selected from Bacillus firmus, Bacillus cereus, Bacillus pumilis, Bacillus amyloliquefaciens, Bacillus subtilis strain GB03, Bacillus subtilis strain QST713, and (C) at least one biological control agent, in particular bacteria, fungi or yeasts, protozoa, viruses, entomopathogenic nematodes, inoculants, botanicals and products produced by microorganisms including proteins or secondary to metabolites.Type: ApplicationFiled: January 22, 2013Publication date: December 11, 2014Inventors: Elke Hellwege, Heike Hungenberg
-
Publication number: 20140356329Abstract: The present invention provides probiotic compositions suitable for reducing the incidence and duration of human illness. In particular, the present invention provides methods and compositions suitable for preventing disease in young children. In some particularly preferred embodiments, the present invention finds use in the prevention respiratory disease in children.Type: ApplicationFiled: August 14, 2014Publication date: December 4, 2014Applicant: DUPONT NUTRITION BIOSCIENCES APSInventors: Gregory Leyer, Arthur Ouwehand
-
Publication number: 20140348795Abstract: A nutraceutical compound designed to promote cellular health, cleanse and replenish a body's gastro-intestinal tract and system, balance a body's natural defense system, keep the immune system high, and keep intestinal bacteria feeding on the correct enzymes is disclosed. More specifically, a nutraceutical compound that includes glutathione, carnosin, B vitamins, amino acids, probiotics, aloe vera, chlorella, spirulina, fruit powders, superfoods, and minerals is disclosed.Type: ApplicationFiled: May 27, 2014Publication date: November 27, 2014Inventors: Helmut Wyzisk, Michael J. Sloggett
-
Publication number: 20140348796Abstract: This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of diabetes (particularly Type 2 diabetes), obesity and related conditions, metabolic syndrome, insulin resistance, and impaired glucose metabolism and consequences thereof, lowering tissue inflammation, treating hepatitis, myositis and cardiovascular conditions.Type: ApplicationFiled: August 8, 2014Publication date: November 27, 2014Inventors: Rémy Burcelin, Didier Carcano, Sampo Lahtinen
-
Publication number: 20140341856Abstract: The method of controlling tomato plant viruses involves inoculation of an uninfected plant with a combination of a cucumber mosaic virus (CMV-KU1) associated with a naturally occurring benign viral satellite RNA with a mixture of two plant growth-promoting rhizobacteria (PGPR) strains, namely, Pseudomonas aeruginosa and Stenotrophomonas rhizophilia, in order to protect plants from the virulent CMV virus while promoting plant growth, yield and fruit quality of the tomato that is lost due to the viral infection. The healthy plant leaves are inoculated with the CMV-KU1 virus at the dicotyledonary stage. Simultaneously, the roots of the tomato plants are inoculated with the PGPR mixture. The satellite RNA component of the combination protects plants against a virulent virus (CMV-16), while the PGPR component compensates for growth, yield, and quality loss of tomato seen in the presence of both CMV-KU1 and CMV-16, in addition to strengthening the protection of plants.Type: ApplicationFiled: May 20, 2013Publication date: November 20, 2014Applicant: KUWAIT UNIVERSITYInventors: NARJES H. DASHTI, MAGDY S. MONTASSER
-
Publication number: 20140335187Abstract: The present invention relates probiotic compositions useful in accelerating alcohol catabolism in a subject.Type: ApplicationFiled: May 12, 2014Publication date: November 13, 2014Applicant: BiOWiSH Technologies, Inc.Inventor: Richard Carpenter
-
Publication number: 20140328803Abstract: Disclosed herein are therapeutic compositions containing non-pathogenic, germination-competent bacterial spores, for the prevention, control, and treatment of gastrointestinal diseases, disorders and conditions and for general nutritional health.Type: ApplicationFiled: June 24, 2014Publication date: November 6, 2014Inventors: Gregory McKenzie, Mary-Jane Lombardo McKenzie, David N. Cook, Marin Vulic, Geoffrey von Maltzahn, Brian Goodman, John Grant Aunins, Matthew R. Henn, David Arthur Berry, Jonathan Winkler
-
Publication number: 20140328932Abstract: The present disclosure refers to a composition with N-acetylcysteine and/or lysozyme; or N-acetylcysteine and microencapsulated gastroprotected lysozyme with pro biotic bacteria for use in the pharmacological treatment of gastric hyperacidity. Said composition is capable of restoring the stomach's own barrier effect, which is lost during the pharmacological treatment of gastric hyperacidity, and of minimising the secondary effects due to said pharmacological treatment.Type: ApplicationFiled: September 10, 2012Publication date: November 6, 2014Inventor: Giovanni MOGNA
-
Patent number: 8877179Abstract: The present invention relates to the field of frozen yoghurt. In particular, the present invention provides frozen yoghurt compositions comprising non-replicating probiotic micro-organisms. These non-replicating probiotic micro-organisms may bioactive heat treated probiotic micro-organisms, for example. The present inventions also relates to health benefits provided by these non-replicating probiotic micro-organisms.Type: GrantFiled: November 11, 2011Date of Patent: November 4, 2014Assignee: Nestec S.A.Inventors: Annick Mercenier, Guenolee Prioult, Sophie Nutten
-
Patent number: 8877208Abstract: The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides methods of inducing an immune response against one or a plurality of pathogens (e.g., vaccinia virus, H5N1 influenza virus, Bacillus anthracis, C. botulinum, Y. pestis, Hepatitis B, and/or HIV, etc.) in a subject (e.g., a human subject) and compositions useful in such methods (e.g., immunogenic composition comprising nanoemulsion and one or a plurality of pathogens (e.g., inactivated by the nanoemulsion) and/or pathogen products and/or pathogen components). Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.Type: GrantFiled: May 26, 2009Date of Patent: November 4, 2014Assignee: The Regents of the University of MichiganInventors: James R. Baker, Jr., Paul E. Makidon, Nicholas J. Mank, Anna U. Bielinska, Luz P. Blanco, Jessica Knowlton
-
Patent number: 8871715Abstract: The present invention relates to compositions and methods for altering cell function. In particular, the present invention provides compositions comprising selenium (e.g., SEL-PLEX) and methods of using the same (e.g., as a therapeutic and/or prophylactic treatment for neurodegenerative disease). Additionally, the present invention demonstrates that specific forms of selenium (e.g., SEL-PLEX) possess the ability to alter expression of genes associated with disease and/or aging while other forms of selenium (e.g., selenomethionine) do not.Type: GrantFiled: October 16, 2006Date of Patent: October 28, 2014Assignee: Alltech, Inc.Inventors: Thomas P. Lyons, Ronan Power
-
Publication number: 20140314719Abstract: The invention relates to treatment of Irritable Bowel Syndrome using probiotic preparations containing viable, metabolically active probiotic bacteria.Type: ApplicationFiled: November 16, 2012Publication date: October 23, 2014Applicant: Multigerm UK Enterprises Ltd.Inventor: Barry Edward Smith
-
Patent number: 8865156Abstract: The invention provides compositions comprising one or more isolated LDH-deficient mutans streptococcus strains and one or more isolated S. oralis strains and/or one or more isolated S. uberis strains. Compositions of the invention are useful to maintain oral health, by for example treating and/or preventing one or more symptoms of dental caries, periodontitis and/or other oral cavity diseases or wounds.Type: GrantFiled: January 31, 2011Date of Patent: October 21, 2014Assignee: Oragenics, Inc.Inventor: Jeffrey D. Hillman
-
Publication number: 20140308248Abstract: A dietary supplement system includes a dietary supplement composition for oral administration by an individual in the morning, the composition, including (a) a telomere maintenance complex including: Purslane extract (aerial parts); Turmeric rhizome extract (95% curcuminoids); Quercetin dehydrate, Cayenne pepper fruit; Vanadium (as vanadyl sulfate); Fenugreek seed; Astragalus root extract, Omega fatty acid complex including linoleic acid; alpha-linolenic acid; oleic acid borage seed oil gamma-linolenic acid), evening primrose oil fish body oil (eicosapentaenoic acid; docosahexaenoic acid); (b) a calorie restriction mimetics and gene expression complex including Trans-resveratrol (from Polygonum cuspidatum root extract); Pterostilbene Fisetin 50% (Buxus microphlla Sieb (stem and leaf; Alpha lipoic acid, Coenzyme Q-10, Betaine HCl, Sulfur (from methylsulfonylmethane); L-Carnitine tartrate; L-Carnitine HCl, and (c) a free radical scavenger complex, including Green tea leaf extract catechin and polyphenols); AnthType: ApplicationFiled: April 25, 2014Publication date: October 16, 2014Inventor: Vincent C. Giampapa
-
Publication number: 20140302986Abstract: The present invention relates to a composition comprising a) Streptomyces microflavus strain NRRL B-50550 and/or a mutant thereof having all the identifying characteristics of the respective strain, and/or at least one metabolite produced by the respective strain that exhibits activity against insects, mites, nematodes and/or phytopathogens and/or a mutant thereof having all the identifying characteristics of the respective strain, and/or at least one metabolite produced by the respective strain that exhibits activity against insects, mites, nematodes and/or phytopathogens and b) at least one further biological control agent selected from specific microorganisms and/or a mutant of it having all identifying characteristics of the respective strain, and/or at least one metabolite produced by the respective strain that exhibits activity against insects, mites, nematodes and/or phytopathogens in a synergistically effective amount.Type: ApplicationFiled: February 10, 2014Publication date: October 9, 2014Applicant: BAYER CROPSCIENCE LPInventors: Wolfram ANDERSCH, Damian CURTIS, Shaohua GUAN, Magalie GUILHABERT-GOYA, Reed Nathan ROYALTY, Frisby Davis SMITH, Bernd SPRINGER, Wolfgang THIELERT, Hong ZHU
-
Patent number: 8852577Abstract: The invention relates to polynucleotides coding for the PPVO viral genome, to fragments of the polynucleotides coding for the PPVO genome and to polynucleotides coding for individual open reading frames (ORFs) of the PPVO viral genome. The invention also relates to recombinant proteins expressed from the above mentioned polynucleotides and to fragments of said recombinant proteins, and to the use of said recombinant proteins or fragments for the preparation of pharmaceutical compositions.Type: GrantFiled: December 17, 2012Date of Patent: October 7, 2014Assignee: AiCuris GmbH & Co. KGInventors: Olaf Weber, Sonja Maria Tennagels, Angela Siegling, Tobias Schlapp, Andrew Allan Mercer, Stephen Bruce Fleming, Hans-Dieter Volk
-
Patent number: 8834853Abstract: The present invention relates to coated dehydrated microorganisms comprising a dehydrated microorganism surrounded by at least one coating, said coating comprising by dry weight at least 25% of hygroscopic salt(s) and wherein the pH of the coating is compatible with viability of the coated dehydrated microorganism. The coating can be partially crystalline, the salt(s) in the coating having preferably a crystallinity degree of up to 60% once applied onto the dehydrated microorganism. The present invention also relates to liquid coating compositions, methods for coating and protecting a dehydrated microorganism. Finally, the present invention relates to a method for the preparation of food products, feed products, consumer healthcare products or agri-products as well as to a food product, feed product, a consumer healthcare product or an agri-product containing such coated dehydrated microorgansims.Type: GrantFiled: August 13, 2010Date of Patent: September 16, 2014Assignee: DuPont Nutrition Bioscience ApsInventors: Isabelle Mazeaud, Kathryn Tse, Jean-Philippe Obert, Claudette Berger, Geoffrey Babin, Patrick Chaigneau, Hans Hedegaard Jensen, Erwan Henri
-
Patent number: 8835170Abstract: The invention provides compositions and methods useful for treating wounds and enhancing wound healing, particularly for diabetic wound healing. One embodiment provides a method of treating a wound comprising administering to a subject in need thereof a therapeutically effective amount of adipose tissue derived stem cells to treat said wound, wherein the cells are cultured in the absence of serum prior to the administration to said subject. Another embodiment provides a method of treating a wound comprising administering to a subject in need thereof a therapeutically effective amount of adipose tissue derived stem cells to treat said wound, wherein the cells are cultured to induce the formation of at least one self-organizing mesenchymal blastema (SOMB) prior to the administration to said subject, wherein said SOMB is formed by culturing adipose tissue derived stem cells in hanging droplets.Type: GrantFiled: October 5, 2007Date of Patent: September 16, 2014Assignee: University of Virginia Patent FoundationInventors: Adam J. Katz, Anna M. Parker